Edition:
United Kingdom

Juno Therapeutics Inc (JUNO.OQ)

JUNO.OQ on NASDAQ Stock Exchange Global Select Market

50.50USD
8:52pm GMT
Change (% chg)

$-8.15 (-13.90%)
Prev Close
$58.65
Open
$59.00
Day's High
$59.00
Day's Low
$50.16
Volume
1,500,960
Avg. Vol
692,354
52-wk High
$63.33
52-wk Low
$17.52

Latest Key Developments (Source: Significant Developments)

Juno Therapeutics Signs Licensing Agreements With Lilly, Oncotracker, And Fred Hutchinson Cancer Research Center
Wednesday, 6 Dec 2017 

Dec 6 (Reuters) - Juno Therapeutics Inc ::JUNO THERAPEUTICS SIGNS LICENSING AGREEMENTS WITH LILLY, ONCOTRACKER, AND FRED HUTCHINSON CANCER RESEARCH CENTER TO ADVANCE ITS BCMA-DIRECTED ENGINEERED T CELL PROGRAM IN MULTIPLE MYELOMA WITH GAMMA SECRETASE INHIBITION.JUNO THERAPEUTICS - THREE LICENSE DEALS TO ADVANCE PROGRAM IN MULTIPLE MYELOMA USING GAMMA SECRETASE INHIBITORS WITH BCMA-DIRECTED CAR T CELLS.JUNO THERAPEUTICS INC - THROUGH ITS AGREEMENT WITH ELI LILLY AND COMPANY, JUNO WILL ACQUIRE A LICENSE TO GSI KNOWN AS LY3039478.JUNO THERAPEUTICS- CO TO ALSO GAIN RIGHTS TO INTELLECTUAL PROPERTY WITHIN FIELD OF COMBINATIONS OF GSIS, BCMA-DIRECTED ENGINEERED T CELLS IN OTHER DEALS.JUNO THERAPEUTICS INC - NO OTHER TERMS FROM THESE THREE TRANSACTIONS WERE DISCLOSED.  Full Article

Juno Therapeutics reports Q3 adjusted loss per share ‍$0.73​
Wednesday, 1 Nov 2017 

Nov 1 (Reuters) - Juno Therapeutics Inc :Juno Therapeutics reports third quarter 2017 financial results.Juno Therapeutics Inc - qtrly ‍revenue $44.8 million versus $20.8 million​.Juno Therapeutics Inc - qtrly loss per share ‍$1.12​.Juno Therapeutics Inc - qtrly adjusted loss per share ‍$0.73​.Juno Therapeutics Inc - ‍expects to be in lower half of 2017 cash burn guidance​.Q3 earnings per share view $-0.80, revenue view $16.2 million -- Thomson Reuters I/B/E/S.  Full Article

Juno Therapeutics and Trianni sign licensing agreement for use of Trianni Transgenic Mouse platform
Wednesday, 18 Oct 2017 

Oct 18 (Reuters) - Juno Therapeutics Inc : :Trianni and Juno Therapeutics sign licensing agreement for use of Trianni Transgenic Mouse platform.Juno - to use Trianni Mouse with its single cell sequencing technology to identify fully-human binders for conversion to chimeric antigen receptors.Juno Therapeutics Inc - ‍no financial details were disclosed​.  Full Article

Juno Therapeutics reports Q2 loss per share $0.64
Thursday, 4 Aug 2016 

Juno Therapeutics Inc : Juno Therapeutics reports second quarter 2016 financial results . Reaffirms cash burn guidance . Qtrly revenue $27.6 million versus $12.5 million . Qtrly loss per share $0.64 .Q2 earnings per share view $-0.41, revenue view $14.3 million -- Thomson Reuters I/B/E/S.  Full Article

Juno Therapeutics Inc - collaboration includes BCMA CAR constructs with fully-human binding domains
Thursday, 4 Aug 2016 

Juno Therapeutics Inc : Collaboration includes BCMA CAR constructs with fully-human binding domains .Juno Therapeutics announces multiple myeloma partnership with memorial sloan kettering cancer center and eureka therapeutics for developing cart cell immunotherapy against multiple novel targets.  Full Article

Juno Therapeutics adds adenosine receptor antagonist through acquisition of redoxtherapies
Thursday, 14 Jul 2016 

Juno Therapeutics Inc : Juno Therapeutics adds adenosine receptor antagonist through acquisition of redoxtherapies . Intend to use in combination with engineered t cells . Upfront consideration for redoxtherapies acquisition was $10 million in cash . Redox is also eligible to receive payments upon achievement of undisclosed clinical, regulatory, and commercial milestones . Acquisition provides Juno with an exclusive license to vipadenant, a small molecule adenosine a2a (a2a) receptor antagonist .Intends to explore adenosine molecule in combination with engineered t cell platform, may over time explore in other areas as well.  Full Article

Juno Therapeutics to resume JCAR015 phase II rocket trial
Tuesday, 12 Jul 2016 

Juno Therapeutics Inc : Juno Therapeutics to resume JCAR015 phase II rocket trial . Rocket trial will continue enrollment using JCAR015 with cyclophosphamide pre-conditioning only .U.S. FDA has removed clinical hold on phase II clinical trial of JCAR015 in adult patients with relapsed or refractory B cell acute lymphoblastic leukemia.  Full Article

Juno Therapeutics reports clinical hold on the JCAR015 Phase II rocket trial
Thursday, 7 Jul 2016 

Juno Therapeutics Inc : Reports clinical hold on the JCAR015 Phase II rocket trial . Says trials and plans for its other CD19-directed CAR-T cell product candidates, including JCAR017, are not affected . Juno will submit requested information to FDA this week . Complete response to clinical hold to also include revised investigator brochure, revised trial protocol, copy of presentation made . Has proposed to FDA to continue rocket trial using JCAR015 with cyclophosphamide pre-conditioning alone . Clinical hold was initiated after two patient deaths last week, which followed recent addition of fludarabine to pre-conditioning regimen . FDA has requested that Juno submit, as a complete response to clinical hold: a revised patient informed consent form .Clinical hold was initiated after two patient deaths last week.  Full Article

Juno Therapeutics reports Q1 loss per share $0.72
Monday, 9 May 2016 

Juno Therapeutics Inc : Q1 non-gaap loss per share $0.78 . Juno therapeutics reports first quarter 2016 financial results . Q1 loss per share $0.72 . Q1 revenue $9.8 million . Q1 revenue view $4.7 million -- Thomson Reuters I/B/E/S .Q1 earnings per share view $-0.52 -- Thomson Reuters I/B/E/S.  Full Article

BRIEF-Juno Therapeutics Signs Licensing Agreements With Lilly, Oncotracker, And Fred Hutchinson Cancer Research Center

* JUNO THERAPEUTICS SIGNS LICENSING AGREEMENTS WITH LILLY, ONCOTRACKER, AND FRED HUTCHINSON CANCER RESEARCH CENTER TO ADVANCE ITS BCMA-DIRECTED ENGINEERED T CELL PROGRAM IN MULTIPLE MYELOMA WITH GAMMA SECRETASE INHIBITION